文献速递心力衰竭与心肌病冠心病

门控心肌灌注/代谢显像对缺血性心衰合并多支病变及糖尿病患者的预后价值

[The prognostic value of gated 99Tcm-MIBI and 18F-FDG myocardial perfusion/metabolic imaging in patients with ischemic heart failure and multi-vessel coronary disease complicated with diabetes].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2026-01-01

本研究为回顾性研究,纳入156例缺血性心力衰竭冠状动脉多支病变合并糖尿病患者,评估99Tcm-MIBI SPECT门控心肌灌注显像与18F-FDG PET/CT门控心肌代谢显像的预后价值。随访5.0(3.3,5.9)年,38例全因死亡,多因素Cox分析示血运重建是全因死亡的保护因素(HR=0.298,95%CI 0.144~0.617,P=0.001)。冬眠心肌范围>10%的患者中,血运重建组累积生存率显著高于药物治疗组。

要点

  • 血运重建是缺血性心衰合并多支病变及糖尿病患者全因死亡的保护因素。
  • 冬眠心肌范围>10%者,血运重建累积生存率优于药物治疗。
  • 冬眠心肌范围≤10%者,血运重建与药物治疗累积生存率无显著差异。

核心结论

  • 在缺血性心力衰竭冠状动脉多支病变合并糖尿病患者中,血运重建术是其预后的保护因素。
  • 冬眠心肌评估有助于对此类患者进行危险分层并指导治疗决策制订,筛选出可能从血运重建术中获益的高危患者。

研究设计与样本

  • 本研究为回顾性研究,纳入2016年4月至2021年1月于首都医科大学附属北京安贞医院行99Tcm-MIBI SPECT门控心肌灌注显像和18F-FDG PET/CT门控心肌代谢显像的缺血性心力衰竭冠状动脉多支病变合并糖尿病患者。
  • 共纳入156例患者,年龄60.0(52.0,66.0)岁,男性131例(84.0%)。
  • 以全因死亡为终点事件,根据随访期间是否发生终点事件将患者分为死亡组和存活组。
  • 采用Cox比例风险回归模型分析全因死亡的独立影响因素,根据冬眠心肌(≤10%或>10%)和治疗策略(血运重建术或药物治疗)进行亚组分析。
  • 绘制Kaplan-Meier生存曲线,采用log-rank检验比较不同冬眠心肌范围及治疗方式组间累积生存率的差异。

主要发现

  • 随访5.0(3.3,5.9)年,38例患者发生全因死亡,118例患者存活。
  • 多因素Cox比例风险回归模型分析示,血运重建术是缺血性心力衰竭冠状动脉多支病变合并糖尿病患者全因死亡的保护因素(HR=0.298,95%CI 0.144~0.617,P=0.001)。
  • 对于冬眠心肌范围>10%的患者,接受血运重建术患者的累积生存率较接受药物治疗的患者高[(86.7±4.0)%比(38.0±10.7)%,log-rank P<0.001]。
  • 在冬眠心肌范围≤10%的患者中,血运重建术与药物治疗的累积生存率差异无统计学意义[(83.3±10.8)%比(75.0±10.8)%,log-rank P>0.05]。

临床怎么用

  • 对此类患者应评估冬眠心肌范围,以进行危险分层。
  • 冬眠心肌范围>10%的患者可能从血运重建术中获益,可据此指导治疗决策。
  • 冬眠心肌范围≤10%的患者中,血运重建与药物治疗的累积生存率无显著差异,治疗选择需综合考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT gated myocardial metabolic imaging combined with 99Tcm-methoxyisobutylisonitrile (MIBI) single-photon emission computed tomography (SPECT) gated myocardial perfusion imaging in patients with ischemic heart failure complicated by multi-vessel coronary disease and diabetes. Methods: This was a retrospective study. Patients with ischemic heart failure complicated by multi-vessel coronary disease and diabetes who underwent 99Tcm-MIBI SPECT gated myocardial perfusion imaging and 18F-FDG PET/CT gated myocardial metabolic imaging between April 2016 and January 2021 at Beijing Anzhen Hospital, Capital Medical University were enrolled. All patients were followed up, with all-cause death as the endpoint. Patients were divided into the death group and the survival group based on whether the endpoint event occurred during the follow-up period. Cox regression model was used to identify the independent influencing factors of all-cause death in these patients. Subgroup analyses were performed according to hibernating myocardium (≤10% or >10%) and therapy strategy (revascularization or medical therapy). Kaplan-Meier survival curves were plotted, and the log-rank test was used to compare the differences in cumulative survival rates between groups with different hibernating myocardium ranges and treatment methods. Results: A total of 156 patients were enrolled, with an age of 60.0 (52.0, 66.0) years, including 131 males (84.0%). During a follow-up of 5.0 (3.3, 5.9) years, 38 all-cause deaths were observed, and 118 patients survived. Multivariate Cox regression analysis showed that revascularization was a protective factor against all-cause death in patients with ischemic heart failure complicated by multivessel coronary artery disease and diabetes mellitus (HR=0.298, 95%CI 0.144-0.617, P=0.001). Kaplan-Meier survival analysis revealed that among patients with hibernating myocardium range >10%, the cumulative survival rate was significantly higher in those who underwent revascularization than in those receiving medical therapy ((86.7±4.0)% vs. (38.0±10.7)%, log-rank P<0.001). In contrast, there was no statistically significant difference in cumulative survival rate between revascularization and medical therapy groups among patients with hibernating myocardium range ≤10% ((83.3±10.8)% vs. (75.0±10.8)%, log-rank P>0.05). Conclusions: In patients with ischemic heart failure complicated by multivessel coronary artery disease and diabetes mellitus, revascularization is a protective factor for prognosis. Assessment of hibernating myocardium facilitates risk stratification and guides treatment decision-making in such patients, helping identify high-risk individuals who may benefit from revascularization. 目的: 评估18F-氟脱氧葡萄糖正电子发射断层扫描/CT门控心肌代谢显像及99Tcm-甲氧基异丁基异腈单光子发射计算机断层门控心肌灌注显像对缺血性心力衰竭冠状动脉多支病变合并糖尿病患者的预后价值。 方法: 本研究为回顾性研究,纳入2016年4月至2021年1月于首都医科大学附属北京安贞医院行99Tcm-甲氧基异丁基异腈单光子发射计算机断层门控心肌灌注显像和18F-氟脱氧葡萄糖正电子发射断层扫描/CT门控心肌代谢显像的缺血性心力衰竭冠状动脉多支病变合并糖尿病患者。对患者进行随访,以全因死亡为终点事件,根据随访期间是否发生终点事件将患者分为死亡组和存活组。采用Cox比例风险回归模型,分析缺血性心力衰竭冠状动脉多支病变合并糖尿病患者发生全因死亡的独立影响因素。根据冬眠心肌(≤10%或>10%)和治疗策略(血运重建术或药物治疗)进行亚组分析。绘制Kaplan-Meier生存曲线,采用log-rank检验比较不同冬眠心肌范围及治疗方式组间累积生存率的差异。 结果: 共纳入156例患者,年龄60.0(52.0,66.0)岁,男性131例(84.0%)。随访5.0(3.3,5.9)年,38例患者发生全因死亡,118例患者存活。多因素Cox比例风险回归模型分析示,血运重建术是缺血性心力衰竭冠状动脉多支病变合并糖尿病患者全因死亡的保护因素(HR=0.298,95%CI 0.144~0.617,P=0.001)。Kaplan-Meier生存分析显示,对于冬眠心肌范围>10%的患者,接受血运重建术患者的累积生存率较接受药物治疗的患者高[(86.7±4.0)%比(38.0±10.7)%,log-rank P<0.001];而在冬眠心肌范围≤10%的患者中,血运重建术与药物治疗的累积生存率差异无统计学意义[(83.3±10.8)%比(75.0±10.8)%,log-rank P>0.05]。 结论: 在缺血性心力衰竭冠状动脉多支病变合并糖尿病患者中,血运重建术是其预后的保护因素;冬眠心肌评估有助于对此类患者进行危险分层并指导治疗决策制订,筛选出可能从血运重建术中获益的高危患者。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Duan LL, Meng JJ, Zheng YQ, et al. [The prognostic value of gated 99Tcm-MIBI and 18F-FDG myocardial perfusion/metabolic imaging in patients with ischemic heart failure and multi-vessel coronary disease complicated with diabetes]. Zhonghua Xin Xue Guan Bing Za Zhi. 2026. PMID: 41529849. doi:10.3760/cma.j.cn112148-20251111-00793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。